Immune cell surface binding sites on B cells, T cells, and NK cells

This term refers to a broad and heterogeneous collection of proteins, including receptors and glycoproteins, expressed on the plasma membranes of B lymphocytes, T lymphocytes, and Natural Killer (NK) cells (Source: Janeway's Immunobiology). These surface binding sites, primarily categorized as Cluster of Differentiation (CD) antigens, are essential for immune recognition, signaling, and effector functions. For example, CD52 is a prominent target found on all three cell types and is the primary target of the monoclonal antibody alemtuzumab (Source: UniProt, FDA). Other critical sites include the T-cell receptor (TCR), B-cell receptor (BCR), and immune checkpoints like PD-1, which are targeted by various biologics to treat malignancies and autoimmune disorders (Source: National Cancer Institute). Polyclonal preparations like anti-thymocyte globulin (ATG) also interact with a wide range of these sites to provide broad immunosuppression (Source: StatPearls). Because the term encompasses a vast array of distinct molecules with diverse biological roles, it is considered a descriptive grouping rather than a single, specific therapeutic target.

Other names

Lymphocyte surface antigensCluster of Differentiation (CD) antigensLeukocyte surface markersLymphocyte receptors

Therapeutic agents targeting these sites typically act through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or by modulating immune signaling pathways such as checkpoint inhibition (Source: PubMed, FDA).